Home Cart Sign in  
Chemical Structure| 1187594-09-7 Chemical Structure| 1187594-09-7

Structure of Baricitinib
CAS No.: 1187594-09-7

Chemical Structure| 1187594-09-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Baricitinib (LY3009104; INCB028050) is a selective, orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

Synonyms: LY3009104; INCB028050

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Baricitinib

CAS No. :1187594-09-7
Formula : C16H17N7O2S
M.W : 371.42
SMILES Code : N#CCC1(N2N=CC(C3=C4C(N=CN3)=NC=C4)=C2)CN(S(=O)(CC)=O)C1
Synonyms :
LY3009104; INCB028050
MDL No. :MFCD27920779
InChI Key :XUZMWHLSFXCVMG-UHFFFAOYSA-N
Pubchem ID :44205240

Safety of Baricitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Baricitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK1

    JAK1, IC50:5.9 nM

  • Tyk2

    TYK2, IC50:53 nM

  • JAK2

    JAK2, IC50:5.7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PBMCs 5 nM 24 h Assess the effects of Baricitinib on PBMCs PMC11732195
primary human monocytes 0.001, 0.01, 0.1, 1.0, 10 μM 2 h To evaluate the effect of Baricitinib on HIV-induced monocyte activation, results showed Baricitinib significantly reduced activation markers. PMC6764124
Calu-3 cells 1 μM 6 h Baricitinib reduced poly I:C-induced CXCL10 gene expression to a similar extent as 5 μM apabetalone. PMC9946890

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Mouse model of Down syndrome Oral 10 mg/kg Once a day, throughout the experiment Baricitinib treatment rescued lethal immune responses and cytokine induction in Dp16 mice. PMC7727402
Mice Down syndrome model Oral 10 mg/kg Once daily for 17 days Baricitinib treatment attenuates global dysregulation of gene expression across multiple organ systems in a mouse model of Down syndrome, particularly in inflammatory-related gene expression. PMC10306300
Mice Primary biliary cholangitis (PBC) model Oral gavage 10 mg/kg Once daily for two weeks After baricitinib treatment, liver inflammation was alleviated, liver-resident Th1-like cells were reduced, serum IgM-AMA levels were significantly decreased, and bile duct damage was relieved. PMC11458754
SCID mice HIV-associated neurocognitive disorder model subcutaneous injection 10 mg/kg and 50 mg/kg once daily for 7 days To evaluate the effect of Baricitinib on behavioral abnormalities and neuroinflammation in HIV-associated neurocognitive disorders, results showed Baricitinib significantly improved cognitive function and reduced neuroinflammation. PMC6764124
Mice vFLIP-chimera mouse model Intraperitoneal injection 10 mg/kg Every 2 days, for a total of 9 treatments Baricitinib alleviated inflammatory pathology and immune dysfunction in vFLIP mice by inhibiting the STAT3 signaling pathway, reducing weight loss and systemic lymphopenia, and decreasing the plasma concentration of multiple pro-inflammatory cytokines. PMC8435761

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03440892 - Recruiting January 2020 Sweden ... More >> Dept of Rheumatology and Inflammation research Recruiting Gothenburg, Sweden Contact: Sofia T Silfverswärd       sofia.silfversward@rheuma.gu.se Less <<
NCT01185353 Arthritis, Rheumatoid Phase 2 Completed - -
NCT01398475 Chronic Inflammatory Disorder|... More >>Arthritis, Rheumatoid Less << PHASE1 COMPLETED 2025-09-11 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, 117597, Singapore Less <<
NCT00902486 Rheumatoid Arthritis Phase 2 Completed - -
NCT01710358 Rheumatoid Arthritis Phase 3 Completed - -
NCT01185353 - Completed - -
NCT01398475 Chronic Inflammatory Disorder|... More >>Arthritis, Rheumatoid Less << PHASE1 COMPLETED 2025-09-11 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, 117597, Singapore Less <<
NCT01721057 Rheumatoid Arthritis Phase 3 Completed - -
NCT01710358 - Completed - -
NCT01469013 Arthritis, Rheumatoid Phase 2 Completed - Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 260-8712 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fukuoka, Japan, 812-0025 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hiroshima, Japan, 730-0017 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hokkaido, Japan, 063-0811 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hyogo, Japan, 673-1462 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ibaragi, Japan, 316-0035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kagoshima, Japan, 890-0067 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kanagawa, Japan, 252-0392 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nagasaki, Japan, 857-1165 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Oita, Japan, 870-0823 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Okayama, Japan, 700-8607 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Osaka, Japan, 586-8521 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tokyo, Japan, 130-0013 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Toyama, Japan, 933-0874 Less <<
NCT01724580 Chronic Atypical Neutrophilic ... More >>Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)|Juvenile Dermatomyositis (JDM)|Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)|Aicardi-Goutières Syndrome (AGS) Less << APPROVED_FOR_MARKETING - Translational Autoinflammatory... More >> Disease (TADS), Bethesda, Maryland, 20892, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Great Ormond Street Hospital, London, WC1N 1EH, United Kingdom Less <<
NCT00902486 - Completed - -
NCT01711359 - Completed - -
NCT01721057 - Completed - -
NCT01711359 Rheumatoid Arthritis Phase 3 Completed - -
NCT01247350 Healthy Volunteer Phase 1 Completed - United States, Hawaii ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Honolulu, Hawaii, United States Less <<
NCT01247350 - Completed - -
NCT01469013 - Completed - -
NCT01885078 Rheumatoid Arthritis Phase 3 Active, not recruiting March 22, 2024 -
NCT03755466 Rheumatoid Arthritis Phase 2 Recruiting November 20, 2023 Japan ... More >> Yukio Nakamura Recruiting Matsumoto, Nagano, Japan, 3908621 Contact: Yukio Nakamura, MD, PhD    +81-263-37-2659    yxn14@aol.jp    Principal Investigator: Yukio Nakamura, MD, PhD Less <<
NCT01536951 - Completed - -
NCT01536951 Healthy Participants Phase 1 Completed - United States, Florida ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Daytona Beach, Florida, United States, 32117 Less <<
NCT01683409 Diabetic Kidney Disease Phase 2 Completed - -
NCT01299285 Healthy Volunteers PHASE1 COMPLETED 2025-03-11 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States Less <<
NCT01721044 Rheumatoid Arthritis Phase 3 Completed - -
NCT03428100 Atopic Dermatitis Phase 3 Recruiting March 1, 2021 -
NCT02576938 Atopic Dermatitis Phase 2 Completed - United States, California ... More >> Dermatology Research Associates Los Angeles, California, United States, 90045 United States, Florida Forward Clinical Trials, Inc Tampa, Florida, United States, 33624 United States, Georgia Medical Dermatology Specialists Atlanta, Georgia, United States, 30342 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, New York Icahn School of Medicine New York, New York, United States, 10029 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Texas Menter Dermatology Research Institute Dallas, Texas, United States, 75246 Center for Clinical Studies Houston, Texas, United States, 77004 Center for Clinical Studies Houston, Texas, United States, 77065 Center for Clinical Studies Webster, Texas, United States, 77598 Japan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fukuoka-shi, Japan, 815-0082 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sapporo, Japan, 060-0063 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Takaoka-shi, Japan, 933-0871 Less <<
NCT02576938 - Completed - -
NCT03334435 Atopic Dermatitis Phase 3 Recruiting August 27, 2021 -
NCT01683409 - Completed - -
NCT01299285 Healthy Volunteers PHASE1 COMPLETED 2025-03-11 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States Less <<
NCT03733301 Atopic Dermatitis Phase 3 Recruiting August 28, 2019 -
NCT01960140 - Completed - -
NCT01960140 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01490632 Psoriasis Ski... More >>n Diseases Skin Diseases, Papulosquamous Less << Phase 2 Completed - -
NCT01721044 - Completed - -
NCT02265705 Rheumatoid Arthritis Phase 3 Completed - Argentina ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ciudad Autonoma de Buenos Aire, Argentina, C1015ABO For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ciudad Autonoma de Buenos Aire, Argentina, C1431FWO For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ciudad Autonoma de Buenos Aire, Argentina, C1440AAD For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Rosario, Argentina, S2000CFJ For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. San Juan, Argentina, J5402DIL For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. San Miguel De Tucuman, Argentina, T4000AXL Brazil For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sao Paulo, Brazil, 04266-010 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. São Paulo, Brazil, 01244-030 China For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China, 100029 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China, 100044 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bengbu, China, 233004 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changsha, China, 410008 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changsha, China, 410011 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chengdu, China, 610041 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Guangzhou, China, 510080 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hefei, China, 230001 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hefei, China, 230022 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jinan, China, 250012 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kunming, China, 650032 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nanjing, China, 210029 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ningbo, China, 315010 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pingxiang, China, 337055 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Shanghai, China, 200001 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Shanghai, China, 200032 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Shanghai, China, 200052 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Shantou, China, 515041 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tianjin, China, 300052 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Wuhan City, China, 430030 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Yancheng, China, 224005 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. ZhuZhou, China, 412007 Less <<
NCT01924299 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT03334396 Atopic Dermatitis Phase 3 Recruiting August 15, 2019 -
NCT01859078 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01490632 - Completed - -
NCT01924299 - Completed - -
NCT03742973 Primary Biliary Cholangitis Phase 2 Not yet recruiting October 15, 2020 United States, California ... More >> Southern California GI and Liver Centers (SCLC) Not yet recruiting Coronado, California, United States, 92118 Contact    619-522-0399       Principal Investigator: Tarek Hassanein          Cedars-Sinai Comprehensive Transplant Center Not yet recruiting Los Angeles, California, United States, 90048 Contact    310-423-6000       Principal Investigator: Vinay Sundaram          UC Davis Transplant Research Not yet recruiting Sacramento, California, United States, 95816 Contact    916-734-0779       Principal Investigator: Christopher Bowlus          United States, Colorado University of Colorado School of Medicine Not yet recruiting Aurora, Colorado, United States, 80045 Contact    728-848-2292       Principal Investigator: Lisa Forman          United States, Florida Florida Digestive Health Specialists Not yet recruiting Lakewood Ranch, Florida, United States, 34211 Contact    941-727-7772       Principal Investigator: Guy W Neff          Schiff Center for Liver Diseases/University of Miami Not yet recruiting Miami, Florida, United States, 33136 Contact    305-243-4615       Principal Investigator: Cynthia Levy          United States, Louisiana Tulane University School of Medicine Not yet recruiting New Orleans, Louisiana, United States, 70112 Contact    504-988-5344       Principal Investigator: Fredric Regenstein          United States, Maryland The Institute for Digestive Health and Liver Disease at Mercy Not yet recruiting Baltimore, Maryland, United States, 21202 Contact    410-332-9356       Principal Investigator: Paul Thuluvath          United States, Michigan Henry Ford Hospital Not yet recruiting Detroit, Michigan, United States, 48202 Contact    313-916-9465       Principal Investigator: Stuart Gordon          United States, Minnesota Mayo Clinic Not yet recruiting Rochester, Minnesota, United States, 55905 Contact    507-284-3917       Principal Investigator: John Eaton          United States, Missouri St Louis University School of Medicine Not yet recruiting Saint Louis, Missouri, United States, 63104 Contact    314-577-8764       Principal Investigator: Bruce Bacon          United States, Ohio UH Cleveland Medical Center Not yet recruiting Cleveland, Ohio, United States, 44106 Contact    216-844-5387       Principal Investigator: Anthony Post          United States, Texas Baylor College of Medicine Not yet recruiting Houston, Texas, United States, 77030 Contact    713-798-1966       Principal Investigator: John Vierling          Italy Azienda Ospedaliera San Gerardo Not yet recruiting Monza, Milano, Italy, 20052 Contact    390392333673       Principal Investigator: Pietro Invernizzi          Istituto Clinico Humanitas Not yet recruiting Rozzano, Milano, Italy, 20089 Contact    390282244556       Principal Investigator: Ana Lleo De Nalda          Azienda Ospedaliera Umberto I Not yet recruiting Ancona, Italy, 60124 Contact    390715963377       Principal Investigator: Marco Marzioni          Puerto Rico Klinical Investigations Group, LLC Not yet recruiting San Juan, Puerto Rico, 00909 Contact    7879197865       Principal Investigator: Federico Rodriguez          University of Puerto Rico, Medical Sciences Campus Not yet recruiting San Juan, Puerto Rico, 00936 Contact    7877540101       Principal Investigator: Esther A. Torres Less <<
NCT01896726 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT03334422 Atopic Dermatitis Phase 3 Active, not recruiting January 9, 2019 -
NCT01896726 - Completed - -
NCT01937026 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01937026 - Completed - -
NCT01859078 - Completed - -
NCT03570749 Alopecia Areata Phase 2 Phase 3 Recruiting March 25, 2022 -
NCT02708095 - Completed - -
NCT03616912 Systemic Lupus Erythematosus Phase 3 Recruiting February 16, 2021 -
NCT02708095 Systemic Lupus Erythematosus Phase 2 Completed - -
NCT03616964 Systemic Lupus Erythematosus Phase 3 Recruiting February 16, 2021 -
NCT02263911 Healthy Participants PHASE1 COMPLETED 2025-12-14 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Tokyo, 192-0071, Japan Less <<
NCT03435081 Atopic Dermatitis Phase 3 Recruiting March 25, 2021 -
NCT01910311 - Completed - -
NCT02759731 Chronic Graft vs Host Disease|... More >>Chronic Graft-Versus-Host Disease Less << PHASE1|PHASE2 COMPLETED 2024-05-30 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT01925144 - Completed - -
NCT01925144 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01910311 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT03773978 Juvenile Idiopathic Arthritis Phase 3 Not yet recruiting September 18, 2021 Brazil ... More >> LMK Serviços Médicos S/S Not yet recruiting Porto Alegre, Rio Grande Do Sul, Brazil, 90540-000 Contact    555130613440       Principal Investigator: Maria Mercedes Caracciolo Picarelli          Hospital de Clinicas de Porto Alegre Not yet recruiting Porto Alegre, RS, Brazil, 90035-903 Contact    555133597662       Principal Investigator: Claiton Viegas Brenol          Faculdade de Medicina de Botucatu Not yet recruiting Botucatu, Sao Paulo, Brazil, 18618-970 Contact    551438801663       Principal Investigator: Claudia Saad Magalhães          Faculdade de Ciências Médicas - UNICAMP Not yet recruiting Campinas, Sao Paulo, Brazil, 13083-887 Contact    551935219421       Principal Investigator: Simone Appenzeller          Universidade Federal de São Paulo - Escola Paulista de Medicina Not yet recruiting São Paulo, Brazil, 04038-001 Contact    551155747627       Principal Investigator: Maria Teresa Terreri          Germany Universitätsklinikum Heidelberg Not yet recruiting Heidelberg, Baden-Württemberg, Germany, 69120 Contact    496221564823       Principal Investigator: Thomas Lutz          Universitätsklinikum Tübingen Not yet recruiting Tübingen, Baden-Württemberg, Germany, 72076 Contact    4970712980901       Principal Investigator: Jasmin Kümmerle-Deschner          Asklepios Klinik Sankt Augustin GmbH Not yet recruiting Saint Augustin, Nordrhein-Westfalen, Germany, 53757 Contact    492149249201       Principal Investigator: Gerd Horneff          HELIOS Klinikum Berlin-Buch Not yet recruiting Berlin, Germany, 13125 Contact    4930940114510       Principal Investigator: Ralf Trauzeddel          Charité Universitätsmedizin Berlin Not yet recruiting Berlin, Germany, 13353 Contact    4930450566528       Principal Investigator: Kirsten Minden          Hamburger Zentrum für Kinder und Jugendrheumatologie Not yet recruiting Hamburg, Germany, 22081 Contact    494020923694       Principal Investigator: Ivan Foeldvari          Japan Kanazawa University Hospital Recruiting Kanazawa, Ishikawa, Japan, 920 8641 Contact    81120360605       Principal Investigator: Masaki Shimizu          Kanagawa Prefectural Childrens Medical Center Not yet recruiting Yokohama, Kanagawa, Japan, 232-0066 Contact    81120360605       Principal Investigator: Tomoyuki Imagawa          Yokohama City University Hospital Not yet recruiting Yokohama, Kanagawa, Japan, 236-0004 Contact    81120360605       Principal Investigator: Shuichi Ito          Miyagi Children's Hospital Recruiting Sendai-shi, Miyagi, Japan, 989 3126 Contact    81120360605       Principal Investigator: Yoshihiro Umebayashi          Osaka Medical College Hospital Not yet recruiting Takatsuki, Osaka, Japan, 569-8686 Contact    81120360605       Principal Investigator: Kosuke Syabana          Saitama Children's Medical Center Not yet recruiting Saitama-shi, Saitama, Japan, 330 8777 Contact    81120360605       Principal Investigator: Yutaka Kawano          Tokyo Medical And Dental University Hospital Not yet recruiting Bunkyo-ku, Tokyo, Japan, 113-8519 Contact    81120360605       Principal Investigator: Masaaki Mori          St. Lukes International Hospital Not yet recruiting Chuo-Ku, Tokyo, Japan, 104 8560 Contact    81120360605       Principal Investigator: Kenichi Yamaguchi          Kagoshima University Hospital Not yet recruiting Kagoshima, Japan, 890-8520 Contact    81120360605       Principal Investigator: Yoshifumi Kawano          Niigata University Medical & Dental Hospital Not yet recruiting Niigata, Japan, 951-8520 Contact    81120360605       Principal Investigator: Utako Kaneko          Mexico CREA de Guadalajara, S.C. Not yet recruiting Guadalajara, Jalisco, Mexico, 44620 Contact    5233336483333       Principal Investigator: Gabriel Vega Cornejo          Hospital Univ. "Dr. José Eleuterio González" Not yet recruiting Monterrey, Nuevo León, Mexico, 64460 Contact    83338623       Principal Investigator: Nadina Eugenia Rubio Perez          Cemdeicy S.C.P. Not yet recruiting Merida, Yucatán, Mexico, 97130 Contact    529992863277       Principal Investigator: Efren Alberto Canul Novelo          Investigación y Biomedicina de Chihuahua, SC Not yet recruiting Chihuahua, Mexico, 31000 Contact    526144373003       Principal Investigator: Cesar Pacheco Tena          Instituto de Investigaciones Aplicadas a la Neurociencia A.C Not yet recruiting Durango, Mexico, 34000 Contact    526181963882       Principal Investigator: Edgar Hernandez Vargas          Russian Federation V.A. Nasonova Research Institute of Rheumatology Not yet recruiting Moscow, Russian Federation, 115522 Contact    74996143965       Principal Investigator: Irina Nikishina          Morozov Children's City Hospital Not yet recruiting Moscow, Russian Federation, 119049 Contact    74959598800       Principal Investigator: Saniya Valieva          Center of Children`s Health Not yet recruiting Moscow, Russian Federation, 119991 Contact    84959671420       Principal Investigator: Ekaterina Alexeeva          First Moscow State Medical University n.a. Sechenov Not yet recruiting Moscow, Russian Federation, 119991 Contact    84992480181       Principal Investigator: Elena Zholobova          St. Petersburg State Pediatric Medical University Not yet recruiting Saint-Petersburg, Russian Federation, 194100 Contact    78122950646       Principal Investigator: Vyacheslav Chasnyk Less <<
NCT02758613 - Completed - -
NCT01968057 - Completed - -
NCT02263911 Healthy Participants PHASE1 COMPLETED 2025-12-14 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Tokyo, 192-0071, Japan Less <<
NCT01870388 Liver Diseases|Hepatic Insuffi... More >>ciency Less << PHASE1 COMPLETED 2025-07-13 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, 33014, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, 32806, United States Less <<
NCT01968057 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01870388 Liver Diseases|Hepatic Insuffi... More >>ciency Less << PHASE1 COMPLETED 2025-07-13 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, 33014, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, 32806, United States Less <<
NCT03026504 Arteritis, Giant Cell PHASE2 COMPLETED 2021-04-12 Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less <<
NCT02758613 Healthy Phase 1 Completed - China ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. Beijing, China, 100034 Less <<
NCT03212638 Healthy Phase 1 Completed - Singapore ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. Singapore, Singapore Less <<
NCT02340104 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1‐877‐CTLILLY Leeds, Yorkshire, United Kingdom, LS2 9LH Less <<
NCT03701789 Rheumatoid Arthritis|Bone Dens... More >>ity|Finger Joints Less << PHASE3 UNKNOWN 2021-10-11 Universitiy Hospital Erlangen,... More >> Erlangen, Bavaria, 91052, Germany Less <<
NCT03773965 Juvenile Idiopathic Arthritis PHASE3 RECRUITING 2025-07-31 Instituto CAICI SRL, Rosario, ... More >>Santa Fe, S2000, Argentina|Centro de Investigaciones Médicas Tucuman, SAN M. DE Tucuman, Tucumán, T4000AXL, Argentina|The Children's Hospital at Westmead, Westmead, New South Wales, 2145, Australia|Royal Children's Hospital, Melbourne, Victoria, 3052, Australia|Perth Children's Hospital, Perth, Western Australia, 6009, Australia|Landeskrankenhaus Bregenz, Bregenz, Vorarlberg, 6900, Austria|Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, 1090, Austria|Cliniques universitaires Saint-Luc, Brussels, Bruxelles-Capitale, Région De, 1200, Belgium|UZ Gent, Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven, Leuven, Vlaams-Brabant, 3000, Belgium|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Faculdade de Medicina da UNESP, Botucatu, S?o Paulo, 18618-686, Brazil|Instituto da Crianca do Hospital das Clinicas da FMUSP, Sao Paulo, S?o Paulo, 05403-000, Brazil|IPITEC, S?o Paulo, 01221-020, Brazil|Universidade Federal de Sao Paulo, S?o Paulo, 04024-002, Brazil|Children's Hospital Capital Institute of Pediatrics, Beijing, Beijing, 100020, China|Beijing Children's hospital, Capital Medical University, Beijing, Beijing, 100045, China|Beijing Peking Union Medical College Hospital, Beijing, Beijing, 100730, China|The Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, 400010, China|The Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, 400065, China|Childrens Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210008, China|Children's Hospital of Soochow University, Suzhou, Jiangsu, 215025, China|Detska nemocnice FN Brno, Brno, Brno-město, 613 00, Czechia|Fakultni nemocnice Motol, Praha, Praha 5, 150 06, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 12808, Czechia|Rigshospitalet, Copenhagen, Hovedstaden, DK-2100, Denmark|Aarhus Universitetshospital, Skejby, Aarhus, Midtjylland, 8200, Denmark|Centre Hospitalier Universitaire de N?mes - H?pital Universitaire Carémeau, N?mes, Gard, 30029, France|H?pitaux Universitaires Paris Sud - H?pital Bicêtre, Le Kremlin-Bicêtre, Paris, 94270, France|Hospices Civils de Lyon - H?pital Femme Mère Enfant, Bron, Rh?ne-Alpes, 69500, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, 86021, France|H?pital Universitaire Necker Enfants Malades, Paris, 75015, France|Universit?tsklinikum Heidelberg, Heidelberg, Baden-Württemberg, 69115, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Baden-Württemberg, 72076, Germany|Asklepios Klinik Sankt Augustin, Sankt Augustin, Nordrhein-Westfalen, 53757, Germany|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|Charité Campus Virchow-Klinikum, Berlin, 13353, Germany|Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari, Hamburg, 22081, Germany|Sir Ganga Ram Hospital, New Delhi, Delhi, 110060, India|Sri Ramachandra MedicaL College & Research Institute, Chennai, Tamil Nadu, 600116, India|Christian Medical College Vellore, Vellore, Tamil Nadu, 632004, India|Meir Medical Center, Kfar Saba, HaMerkaz, 4428164, Israel|Schneider Children's Medical Center, Petah Tikva, HaMerkaz, 49202, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, 5262100, Israel|Rambam Health Care Campus, Haifa, ?eifā, 3109601, Israel|University of Naples Federico II, Napoli, Campania, 80131, Italy|IRCCS Istituto Giannina Gaslini, Genova, Liguria, 16147, Italy|Centro Specialistico Ortopedico Traumatologico Gaetano Pini - CTO, Milano, Lombardia, 20122, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Lombardia, 20122, Italy|Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, 25123, Italy|Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti, Chieti, 66100, Italy|Ospedale Infantile Burlo Garofolo, Trieste, 34137, Italy|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Kanagawa Children's Medical Center, Yokohama, Kanagawa, 232-8555, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, 236-0004, Japan|Miyagi Children's Hospital, Sendai, Miyagi, 989-3126, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, 569-8686, Japan|Saitama Children's Medical Center, Saitama-shi, Saitama, 330 8777, Japan|Institute of Science Tokyo Hospital, Bunkyō, Tokyo, 113-8519, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, 162-8666, Japan|Chiba Children's Hospital, Chiba, 266-0007, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|Niigata University Medical & Dental Hospital, Niigata, 951-8520, Japan|St. Luke's International Hospital, Tokyo, 104-8560, Japan|Clinstile, S.A. de C.V., Mexico, Distrito Federal, 6700, Mexico|Crea de Guadalajara, Guadalajara, Jalisco, 44600, Mexico|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, 66460, Mexico|Investigacion y Biomedicina de Chihuahua, Chihuahua, 31000, Mexico|Instituto de Investigaciones Clínicas para la Salud, Durango, 34000, Mexico|Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji, Warsaw, Mazowieckie, 02-637, Poland|Wojewódzki Specjalistyczny Szpital Dzieci?cy im. ?w. Ludwika w Krakowie, Krakow, Ma?opolskie, 31-503, Poland|Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, ?ód?, ?ódzkie, 91-738, Poland|Federal State Budgetary Scientific Institution Research Institute Rheumatology named after V.A.Nasonova, Moscow, Moskva, 115522, Russian Federation|Scientific Center of Children's Health, Moscow, Moskva, 119991, Russian Federation|Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona [Barcelona], 8950, Spain|Hospital Infantil Universitario Ni?o Jesús, Madrid, Madrid, Comunidad De, 28009, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, 28034, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital Universitari i Politecnic La Fe, València, 46026, Spain|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, 34098, Turkey|9 Eylul University Hospital, Izmir, 35340, Turkey|Bristol Royal Hospital for Children, Bristol, Bristol, City Of, BS2 8BJ, United Kingdom|Alder Hey Children's Hospital, Liverpool, England, L14 5AB, United Kingdom|University College Hospital - London, London, Greater London, NW1 2BU, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, London, London, City Of, WC1N 3JH, United Kingdom|Oxford University Hospitals - Nuffield Orthopaedic Centre, Oxford, Oxfordshire, OX3 7LD, United Kingdom|Sheffield Children's Hospital, Sheffield, S10 2TH, United Kingdom Less <<
NCT03559270 Atopic Dermatitis PHASE3 TERMINATED 2022-06-13 University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35233, United States|Johnson Dermatology, Fort Smith, Arkansas, 72916, United States|California Dermatology & Clinical Research Institute, Encinitas, California, 92024, United States|First OC Dermatology, Fountain Valley, California, 92708, United States|Center For Dermatology Clinical Research, Inc., Fremont, California, 94538, United States|Keck School of Medicine University of Southern California, Los Angeles, California, 90033, United States|Wallace Medical Group, Inc., Los Angeles, California, 90056, United States|University of California Davis-Dermatology, Sacramento, California, 95816, United States|Medical Center For Clinical Research, San Diego, California, 92108, United States|University Clinical Trials, Inc., San Diego, California, 92123, United States|Southern California Dermatology, Inc., Santa Ana, California, 92701, United States|Clinical Science Institute, Santa Monica, California, 90404, United States|Care Access Research-Walnut Creek, Walnut Creek, California, 94598, United States|GWU/Medical Faculty Associates, Washington, District of Columbia, 20037, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, 32256, United States|Olympian Clinical Research, Largo, Florida, 33770, United States|Miami Dermatology and Laser Research, Miami, Florida, 33173, United States|Riverchase Dermatology and Cosmetic Surgery, Pembroke Pines, Florida, 33028, United States|University of South Florida, Tampa, Florida, 33612, United States|ForCare Clinical Research, Tampa, Florida, 33613-1244, United States|Dermatologic Surgery Specialists, PC, Macon, Georgia, 31217, United States|Advanced Medical Research, Sandy Springs, Georgia, 30328, United States|Advanced Clinical Research LLC, Meridian, Idaho, 83642, United States|Northwestern University, Chicago, Illinois, 60611, United States|University Dermatology, Darien, Illinois, 60561, United States|Arlington Dermatology, Rolling Meadows, Illinois, 60008, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, 46250, United States|The Indiana Clinical Trials Center, Plainfield, Indiana, 46168, United States|The South Bend Clinic Center for Research, South Bend, Indiana, 46617, United States|Forefront Research, Louisville, Kentucky, 40241, United States|Dermatology and Skin Cancer Specialists, Rockville, Maryland, 20850, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Great Lakes Research Group, Inc., Bay City, Michigan, 48706, United States|Central Dermatology PC, Saint Louis, Missouri, 63117, United States|Skin Specialists, P.C, Omaha, Nebraska, 68144, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, 10003, United States|DermResearchCenter of New York, Inc, Stony Brook, New York, 11790, United States|Bexley Dermatology Research, Bexley, Ohio, 43209, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Wright State Univ School of Medicine, Fairborn, Ohio, 45324, United States|Oregon Dermatology and Research Center, Portland, Oregon, 97210, United States|OHSU Center for Health and Healing, Portland, Oregon, 97239, United States|The Pennsylvania Centre for Dermatology, LLC, Exton, Pennsylvania, 19341, United States|Clinical Partners, LLC, Johnston, Rhode Island, 02919, United States|Clinical Research Center of the Carolinas, Charleston, South Carolina, 29407, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Bellaire Dermatology, Bellaire, Texas, 77401, United States|Modern Research Associates, Dallas, Texas, 75231, United States|Austin Institute for Clinical Research, Pflugerville, Texas, 78660, United States|Texas Dermatology and Laser Specialists, San Antonio, Texas, 78218, United States|University of Utah MidValley Dematology, Murray, Utah, 84107, United States|MultiCare Good Samaritan Hospital, Tacoma, Washington, 98405, United States|Kirk Barber Research, Calgary, Alberta, T2G 1B1, Canada|Beacon Dermatology, Calgary, Alberta, T3E 0B2, Canada|Alberta DermaSurgery Centre, Edmonton, Alberta, T6G 1C3, Canada|Dr. Chih-ho Hong Medical Inc., Surrey, British Columbia, V3R 6A7, Canada|Enverus Medical Research, Surrey, British Columbia, V3V 0C6, Canada|Simcoderm Medical & Surgical Dermatology Centre, Barrie, Ontario, L4M 7G1, Canada|Kingsway Clinical Research, Etobicoke, Ontario, M8X 1Y9, Canada|Lynderm Research Inc., Markham, Ontario, L3P1X2, Canada|Allergy Research Canada Inc., Niagara Falls, Ontario, L2H 1H5, Canada|SKiN Centre for Dermatology, Peterborough, Ontario, K9J 5K2, Canada|The Centre for Dermatology, Richmond Hill, Ontario, L4B 1A5, Canada|York Dermatology Center, Richmond Hill, Ontario, L4C 9M7, Canada|Medicor Research Inc, Sudbury, Ontario, P3A 1W8, Canada|K. Papp Clinical Research, Waterloo, Ontario, N2J 1C4, Canada|XLR8 Medical Research, Windsor, Ontario, N8W 1E6, Canada|Innovaderm Research Inc, Montreal, Quebec, H2X 2V1, Canada|Centre de Recherche Dermatologique de Quebec Metropolitain, Quebec, G1V 4X7, Canada|Dr. Samuel Sanchez PSC, Caguas, 00727, Puerto Rico|Office of Dr. Alma M. Cruz, Carolina, 00985, Puerto Rico|Ponce School of Medicine CAIMED Center, Ponce, 00716, Puerto Rico|GCM Medical Group, PSC - Hato Rey Site, San Juan, 00917, Puerto Rico Less <<
NCT02340104 - Completed - -
NCT04131738 Graft-versus-host-disease|Graf... More >>t Vs Host Disease Less << PHASE1 COMPLETED 2022-08-17 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT05189106 Amyotrophic Lateral Sclerosis|... More >>Alzheimer Disease|Mild Cognitive Impairment Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-06-01 Massachusetts General Hospital... More >> - ALS Site, Boston, Massachusetts, 02129, United States|Massachusetts General Hospital - AD Site, Charlestown, Massachusetts, 02129, United States Less <<
NCT04320277 Pharmacological Action PHASE2|PHASE3 UNKNOWN 2020-07-30 Fabrizio Cantini, Prato, Tusca... More >>ny, 59100, Italy Less <<
NCT05361109 Dermatomyositis PHASE2 WITHDRAWN 2023-03-31 University of Washington Medic... More >>al Center, Seattle, Washington, 98195, United States Less <<
NCT06490757 Inflammatory Hepatocellular Ad... More >>enoma Less << PHASE2 NOT_YET_RECRUITING 2028-09-02 -
NCT05852171 Mastitis Chronic|Idiopathic Gr... More >>anulomatous Mastitis Less << PHASE2 RECRUITING 2025-10-31 The First Affiliated Hospital,... More >> Zhejiang University School of Medicine, Hangzhou, Zhejiang, China Less <<
NCT05446831 ITP|Immune Thrombocytopenia PHASE2 UNKNOWN 2023-12-01 Peking University Insititute o... More >>f Hematology, Peking University People's Hospital, Beijing, Beijing, 100010, China Less <<
NCT06797310 Alopecia Areata PHASE2 NOT_YET_RECRUITING 2026-12-31 National Taiwan University Hos... More >>pital, Taipei, 100, Taiwan Less <<
NCT04517253 Nakajo-Nishimura Syndrome|Chro... More >>nic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome|STING-Associated Vasculopathy With Onset in Infancy|Aicardi Goutieres Syndrome Less << PHASE2|PHASE3 ACTIVE_NOT_RECRUITING 2025-11-24 Nara Medical University Hospit... More >>al, Kashihara, Nara, 634-0813, Japan|Tokyo Medical And Dental University Medical Hospital, Bunkyō, Tokyo, 113-8519, Japan|National Center For Child Health And Development, Setagaya-ku, Tokyo, 157-8535, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Wakayama Medical University Hospital, Wakayama, 641-0012, Japan Less <<
NCT04399798 Corona Virus Infection PHASE2 UNKNOWN 2020-11-15 -
NCT05950542 Vitiligo, Generalized NOT_YET_RECRUITING 2024-12-30 -
NCT04340232 COVID-19 PHASE2|PHASE3 WITHDRAWN 2025-10-21 University of Colorado, Denver... More >>, Aurora, Colorado, 80045, United States Less <<
NCT04901325 Pyoderma Gangrenosum|Skin Dise... More >>ases|Wound Heal|Pyoderma|Skin Ulcer Less << PHASE2 RECRUITING 2025-05-31 Oregon Health and Science Univ... More >>ersity, Portland, Oregon, 97239, United States Less <<
NCT06475820 Acute Lymphoblastic Leukemia|A... More >>cute Myeloid Leukemia|Biphenotypic Acute Leukemia|Malignant Lymphoma|Myelodysplastic Syndromes Less << PHASE2|PHASE3 ACTIVE_NOT_RECRUITING 2027-04-01 Dmitry Rogachev National Medic... More >>al Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, 11198, Russian Federation Less <<
NCT06548802 Pulmonary Injury After Intrace... More >>rebral Hemorrhage Less << PHASE1|PHASE2 RECRUITING 2025-06-26 Tianjin Medical University Gen... More >>eral Hospital, Tianjin, Tianjin, 300052, China Less <<
NCT03921554 Aicardi Goutieres Syndrome PHASE2 COMPLETED 2024-03-25 Children's Hospital of Philade... More >>lphia, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT05074420 Covid19|Corona Virus Infection PHASE3 RECRUITING 2025-05-26 Arnold Palmer Hospital for Chi... More >>ldren, Orlando, Florida, 32806, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|The University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|University of Texas Medical Branch, Galveston, Texas, 77555, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Centre Hospitalier Régional de la Citadelle, Liège, 4000, Belgium|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90410000, Brazil|Centro de Pesquisa Sao Lucas, Campinas, S?o Paulo, 13034-685, Brazil|Instituto de Pesquisa clinica de Campinas, Campinas, S?o Paulo, 13060-080, Brazil|CECIP - Centro de Estudos do Interior Paulista, Jau, S?o Paulo, 17201130, Brazil|Pesquisare Saude, Santo André, S?o Paulo, 09080-110, Brazil|Instituto Nacional de Pediatria, Mexico City, Distrito Federal, 04530, Mexico|Hospital Infantil de Mexico Federico Gomez, Mexico City, 06720, Mexico|Hospital Universitario de Araba (HUA)- Hospital Txagorritxu, Vitoria-Gasteiz, Araba, 01009, Spain|Hospital Universitario La Paz, Madrid, Madrid, Comunidad De, 28046, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31009, Spain|Hospital Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain Less <<
NCT05792462 NMO Spectrum Disorder PHASE1|PHASE2 RECRUITING 2025-12-30 Tianjin Medical University Gen... More >>eral Hospital, Tianjin, Tianjin, 300052, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.46mL

2.69mL

1.35mL

26.92mL

5.38mL

2.69mL

References

 

Historical Records

Categories